Organization (Industry)
Adaptimmune Therapeutics PLC
ClinicalTrials.gov lists Adaptimmune Therapeutics PLC as lead sponsor of 13 trials. It has 24 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through October, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to October, under the 5 a year the method needs.
This page covers Adaptimmune Therapeutics PLC: 13 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Neoplasm Metastasis | 8 |
| Head and Neck Neoplasms | 3 |
| Liposarcoma | 3 |
| Liposarcoma, Myxoid | 3 |
| Melanoma | 3 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2021 | 2 |
| 2020 | 3 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2013 | 2 |
| 2011 | 1 |
| 2009 | 1 |
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (24)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials | Ownership basis |
|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | Liposarcoma | Phase 1 | 3 | Generic, not holder |
| CYCLOPHOSPHAMIDE | Sarcoma | Phase 1 | 3 | Generic, not holder |
| CYCLOPHOSPHAMIDE | Liposarcoma, Myxoid | Phase 1 | 3 | Generic, not holder |
| FLUDARABINE | Liposarcoma | Phase 1 | 3 | Generic, not holder |
| FLUDARABINE | Sarcoma | Phase 1 | 3 | Generic, not holder |
Showing 5 of 24 active programs.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials | Ownership basis |
|---|---|---|
| CYCLOPHOSPHAMIDE | 3 | Generic, not holder |
| FLUDARABINE | 3 | Generic, not holder |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 30% hit target (n=10) | 50% on time (n=8) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Frontiers in oncology | 1 |
| Journal for immunotherapy of cancer | 1 |
| Journal of hepatology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 28 | 11 | 2024-12-31 |
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts; non-USD filers converted to USD at the annual average rate.
| Fiscal year | Revenue | Net income | R&D |
|---|---|---|---|
| 2024 | $178M | -$70.8M | $149M |
| 2023 | $60.3M | -$114M | $127M |
| 2022 | $27.1M | -$165M | $128M |
| 2021 | $6.15M | -$158M | $111M |
| 2020 | $3.96M | -$130M | $91.6M |
| 2019 | $1.12M | -$137M | $97.5M |
| 2018 | $59.5M | -$95.5M | $98.3M |
| 2017 | $37.8M | -$70.1M | $87.4M |
| 2016 | $14.2M | -$71.6M | $63.8M |
| 2015 | $9.87M | -$22.1M | $24.1M |
Cash runway about 15 months at the end of FY2024. Estimate, derived not reported: $152M of cash and investments over $119M a year of net cash used in operations, averaged over the 3 reported fiscal years to FY2024.
Financing and grant events (31)
Shown in this order: most recent first; amounts in US dollars.
| Date | Round type | Amount | Source |
|---|---|---|---|
| 2025-11-13 | Other financing | not disclosed | EDGAR offerings |
| 2025-07-31 | Other financing | not disclosed | SEC extracted |
| 2025-07-31 | Other financing | not disclosed | SEC extracted |
| 2025-07-27 | Other financing | not disclosed | SEC extracted |
| 2025-07-27 | Other financing | not disclosed | SEC extracted |
Showing 5 of 31 events.
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| ADAPTIMMUNE LIMITED | MODULE 5, CELL & GENE THERAPY CATAPULT MANUFACTURING CENTRE GUNNELS WOOD ROAD, STEVENAGE, GB | EMA | |
| ADAPTIMMUNE LIMITED | 60 JUBILEE AVENUE, MILTON PARK MILTON, ABINGDON, GB | EMA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2024 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2024 | not disclosed | not disclosed |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Icon Plc | Uses vendor | 1 |
| University of Pennsylvania | Co sponsors trial with | 1 |
| Inge Marie Svane | Co sponsors trial with | 1 |
Latest dated events (75)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-13 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-31 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-31 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-27 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-07-27 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 75 events.
Biomarker capability evidence (95)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 95 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.